皮肤癣菌甲与皮肤感染中特比萘芬耐药性的可靠快速鉴定
研究分析了2013至2021年5634株皮肤癣菌,发现特比萘芬耐药比例从0.63%升至1.3%,所有耐药株均存在SQLE突变,MIC范围为0.004-16.0 μg/mL,MIC低至0.015 μg/mL即可导致临床耐药。作者提出以0.015 μg/mL为预测临床治疗失败的最低折点,并推荐0.2 μg/mL特比萘芬琼脂生长法与SQLE测序作为快速可靠检测方法。
要点
- 2013至2021年,特比萘芬耐药皮肤癣菌感染比例由0.63%上升至1.3%。
- 0.83%(47/5634)的毛癣菌体外表现特比萘芬耐药,均检出SQLE突变。
- MIC低至0.015 μg/mL即可导致标准口服剂量临床耐药。
核心结论
- 基于数据提出MIC 0.015 μg/mL作为预测标准口服特比萘芬治疗皮肤癣菌感染临床失败的最低折点。
- 提出在含0.2 μg/mL特比萘芬的沙氏葡萄糖琼脂上生长及SQLE测序作为不依赖产孢的快速可靠耐药检测方法。
研究设计与样本
- 2013至2021年连续分离5634株毛癣菌,通过含0.2 μg/mL特比萘芬的沙氏葡萄糖琼脂上菌丝生长筛选耐药,对保留生长者行SQLE测序,并用肉汤微量稀释法测定MIC。
主要发现
- 8年间,耐药皮肤癣菌感染比例从2013年的0.63%上升至2021年的1.3%。
- 常规体外表型筛选鉴定0.83%(47/5634)的毛癣菌株具有体外特比萘芬耐药。
- 分子筛查在所有耐药株中检出SQLE突变;T. rubrum中检出L393F、L393S、F397L、F397I、F397V、Q408K、F415I、F415S、F415V、H440Y或A398_A399_G400缺失,以L393F和F397L最常见;T. mentagrophytes/T. interdigitale复合株中除一株为L393S外均为F397L。
- 全部47株耐药株的MIC显著高于特比萘芬敏感对照,突变相关MIC范围为0.004-16.0 μg/mL。
- MIC低至0.015 μg/mL即可赋予对标准特比萘芬剂量的临床耐药。
关键数值与推荐
- 提出MIC 0.015 μg/mL作为预测标准口服特比萘芬治疗皮肤癣菌感染临床失败的最低折点。
- 提出在含0.2 μg/mL特比萘芬的沙氏葡萄糖琼脂上生长及SQLE测序作为快速可靠检测耐药的不依赖产孢方法。
局限性
- 原文未述局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Fungal infections are the most frequent dermatoses. The gold standard treatment for dermatophytosis is the squalene epoxidase (SQLE) inhibitor terbinafine. Pathogenic dermatophytes resistant to terbinafine are an emerging global threat. Here, we determine the proportion of resistant fungal skin infections, analyse the molecular mechanisms of terbinafine resistance, and validate a method for its reliable rapid identification. METHODS: Between 2013 and 2021, we screened 5634 consecutively isolated Trichophyton for antifungal resistance determined by hyphal growth on Sabouraud dextrose agar medium containing 0.2 μg/mL terbinafine. All Trichophyton isolates with preserved growth capacity in the presence of terbinafine underwent SQLE sequencing. Minimum inhibitory concentrations (MICs) were determined by the broth microdilution method. RESULTS: Over an 8-year period, the proportion of fungal skin infections resistant to terbinafine increased from 0.63% in 2013 to 1.3% in 2021. Our routine phenotypic in vitro screening analysis identified 0.83% (n = 47/5634) of Trichophyton strains with in vitro terbinafine resistance. Molecular screening detected a mutation in the SQLE in all cases. Mutations L393F, L393S, F397L, F397I, F397V, Q408K, F415I, F415S, F415V, H440Y, or A398 A399 G400 deletion were detected in Trichophyton rubrum. Mutations L393F and F397L were the most frequent. In contrast, all mutations detected in T. mentagrophytes/T. interdigitale complex strains were F397L, except for one strain with L393S. All 47 strains featured significantly higher MICs than terbinafine-sensitive controls. The mutation-related range of MICs varied between 0.004 and 16.0 μg/mL, with MIC as low as 0.015 μg/mL conferring clinical resistance to standard terbinafine dosing. CONCLUSIONS: Based on our data, we propose MIC of 0.015 μg/mL as a minimum breakpoint for predicting clinically relevant terbinafine treatment failure to standard oral dosing for dermatophyte infections. We further propose growth on Sabouraud dextrose agar medium containing 0.2 μg/mL terbinafine and SQLE sequencing as fungal sporulation-independent methods for rapid and reliable detection of terbinafine resistance.
引用
- Blanchard G, Amarov B, Fratti M, et al. Reliable and rapid identification of terbinafine resistance in dermatophytic nail and skin infections. J Eur Acad Dermatol Venereol. 2023. PMID: 37319111. doi:10.1111/jdv.19253
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。